[1] H. N. Abramson, “The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets in sentence style,” Clin Lymphoma Myeloma Leuk title, vol.18, no.9, pp. 611-627, 2018.
[2] P. L. Bergsagel, W. M. Kuehl, “Chromosome translocations in multiple myeloma in sentence style,” Oncogene title, vol.20, no.40, pp. 5611-5622, 2001.
[3] J. De Vos, T. Thykjaer, K. Tarte, M. Ensslen, P. Raynaud, G. Requirand et al, “Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays in sentence style,” Oncogene title, vol.21, no.44, pp. 6848-6857, 2002.
[4] F. Cottini, T. Hideshima, C. Xu, M. Sattler, M. Dori, L. Agnelli et al, “Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers in sentence style,” Nat Med title, vol.20, no.6, pp. 599-606, 2014.
[5] D. K. Walters, X. Wu, R. C. Tschumper, B. K. Arendt, P. M. Huddleston, K. J. Henderson et al, “Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX in sentence style,” Leukemia title, vol.25, no.8, pp. 1344-1353, 2011.
[6] L. Mazzera, M. Abeltino, G. Lombardi, A. M. Cantoni, R. Ria, M. Ricca et al, “Functional interplay between NF-kappaB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma in sentence style,” Haematologica title, vol.104, no.12, pp. 2465-2481, 2019.
[7] S. Gao, C. Geng, T. Song, X. Lin, J. Liu, Z. Cai et al, “Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase in sentence style,” J Biol Chem title, vol.292, no.9, pp. 3683-3691, 2017.
[8] J. Mei, Y. Zhai, H. Li, F. Li, X. Zhou, P. Song et al, “Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China in sentence style,” J Cancer Res Clin Oncol title, vol.144, no.11, pp. 2263-2273, 2018.
[9] S. Van Wier, E. Braggio, A. Baker, G. Ahmann, J. Levy, J. D. Carpten et al, “Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma in sentence style,” Haematologica title, vol.98, no.10, pp. 1586-1592, 2013.
[10] T. G. Lugo, O. N. Witte, “The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc in sentence style,” Mol Cell Biol title, vol.9, no.3, pp. 1263-1270, 1989.
[11] J. Lin, R. Arlinghaus, “Activated c-Abl tyrosine kinase in malignant solid tumors in sentence style,” Oncogene title, vol.27, no.32, pp. 4385-4391, 2008.
[12] D. Srinivasan, R. Plattner, “Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells in sentence style,” Cancer Res title, vol.66, no.11, pp. 5648-5655, 2006.
[13] A. Pandiella, X. Carvajal-Vergara, S. Tabera, G. Mateo, N. Gutierrez, J. F. San Miguel, “Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents in sentence style,” British journal of haematology title, vol.123, no.5, pp. 858-868, 2003.
[14] P. Vigneri, J. Y. Wang, “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase in sentence style,” Nature medicine title, vol.7, no.2, pp. 228-234, 2001.
[15] S. Kosztolanyi, R. Kiss, L. Atanesyan, A. Gango, K. de Groot, M. Steenkamer et al, “High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma in sentence style,” J Mol Diagn title, vol.20, no.6, pp. 777-788, 2018.
[16] S. Doi, Y. Tashiro, N. Yoshinaga, W. Kishimoto, T. Hamada, C. Ueda et al, “[BCR-ABL1-positive myelodysplastic syndrome with neutropenia and anemia treated successfully with imatinib mesylate] in sentence style,” Rinsho Ketsueki title, vol.61, no.5, pp. 455-461, 2020.
[17] K. Miki, N. Obara, K. Makishima, T. Sakamoto, M. Kusakabe, T. Kato et al, “An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature in sentence style,” Case Rep Hematol title, vol.2018, no., pp. 7863943, 2018.
[18] T. Otto, P. Sicinski, “Cell cycle proteins as promising targets in cancer therapy in sentence style,” Nature reviews Cancer title, vol.17, no.2, pp. 93-115, 2017.
[19] J. Colicelli, “ABL tyrosine kinases: evolution of function, regulation, and specificity in sentence style,” Sci Signal title, vol.3, no.139, pp. re6, 2010.
[20] H. Huang, W. Guo, L. He et al, “Evidence for ABL Amplification in Multiple Myeloma and Its Role in Treatment,” Research Square, DOI: 10.21203/rs.3.rs-48781/v1